08:06 AM EDT, 08/23/2024 (MT Newswires) -- Moderna ( MRNA ) said Friday that it has secured the European Commission's marketing approval for its respiratory syncytial virus, or RSV, vaccine, mRESVIA, to safeguard adults aged at least 60 years against lower respiratory tract disease resulting from the RSV infection.

The approval, which is valid across all EU member states along with Iceland, Liechtenstein, and Norway, comes after a Positive Opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, the company said.

The approval is supported by data from a phase 3 clinical study that included 37,000 adults aged at least 60 years in 22 countries, Moderna ( MRNA ) added.

Price: 82.06, Change: +1.02, Percent Change: +1.26